Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice

Journal of Clinical Investigation

Volumn 99, Issue 12, 1997, Pages 2858-2866

  Zhang, Sunny H ^a,c   Reddick, Robert L ^a,d   Avdievich, Elena ^a   Surles, L Kester ^a   Jones, Robert G ^a   Reynolds, John B ^a   Quarfordt, Steven H ^b   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apolipoprotein AI; Disease models; Hypercholesterolemia; Hypocholesterolemic agent; Inflammation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; FEMALE; HYPERLIPOPROTEINEMIA TYPE 3; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030923925     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119479     Document Type: Article

References (38)

1. Schwartz, C.J., A.J. Valente, E.A. Sprague, J.L. Kelley, and R.M. Nerem. 1991. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol. 14:I1-I16.
2. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
3. Parthasarathy, S., S.G. Young, J.L. Witztum, R.C. Pittmann, and D. Steinberg. 1986. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:641-644.
4. Naruszewicz, M., T.E. Carew, R.C. Pittman, J.L. Witztum, and D. Steinberg. 1984. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J. Lipid Res. 25: 1206-1213.
5. Yamamoto, A., Y. Matsuzawa, S. Yokoyama, T. Funahashi, T. Yamamura, and B. Kishino. 1986. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am. J. Cardiol. 57:29H-35H.
6. Kita, T., Y. Nagano, M. Yokode, K. Ishii, N. Kume, A. Ooshima, H. Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:5928-5931.
7. Nagano, Y., T. Nakamura, Y. Matsuzawa, M. Cho, Y. Ueda, and T. Kita. 1992. Probucol and atherosclerosis in Watanabe heritable hyperlipidemic rabbit - long-term antiatherogenic effect and effects on established plaques. Atherosclerosis. 92:131-140.
8. Daugherty, A., B.S. Zweifel, and G. Shonfeld. 1991. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyper-lipidemic rabbits. Br. J. Pharmacol. 103:1013-1018.
9. Braesen, J.H., U. Beisiegel, and A. Niendolf. 1995. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits. Virchows Arch. 426:179-188.
10. Sasahara, M., E.W. Raines, A. Chait, T.E. Carew, D. Steinberg, P.W. Wahl, and R. Ross. 1994. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94:155-164.
11. Stein, Y., O. Stein, B. Delplanque, J.D. Fesmire, D.M. Lee, and P. Alaupovic. 1989. Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. Atherosclerosis. 75:145-155.
12. Walldius, G., U. Erikson, A.G. Olsson, L. Bergstrand, K. Hadell, J. Johansson, L. Kaijser, C. Lassvik, J. Molgaard, and S. Nilsson. 1994. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 74:875-883.
13. Regnstrom. J., G. Walldius, S. Nilsson, L.S. Elinder, J. Johansson, J. Molgaard, I. Holme, A.G. Olsson, and J. Nilsson. 1996. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis. 125:217-229.
14. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (Wash. DC). 258:468-471.
15. Plump, A.S., D.J. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
16. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apolipoprotein E: evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-147.
17. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
18. Piedrahita, J.A., S.H. Zhang, J.R. Hagaman, P.M. Oliver, and N. Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:4471-4475.
19. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked reduction of high density lipoprotcin cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89:7134-7138.
20. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28:1379-1382.
21. France, D.S., T.E. Hughes, R. Miserendino, J.A. Spirito, J. Babiak, J.B. Eskesen, C. Tapparelli, and J.R. Paterniti, Jr. 1989. Nonimmunochemical quantitation of mammalian apolipoprotein AI in whole serum or plasma by nonreducing gel electrophoresis. J. Lipid. Res. 30:1997-2004.
22. Paigen, B., A. Morrow, P.A. Holmes, D. Mitchell, and R.A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:231-240.
23. Baker, S.G., B.I. Joffe, D. Mendelsohn, and H.C. Seftel. 1982. Treatment of homozygous familial hypercholesterolaemia with probucol. S. Afr. Med. J. 62:7-11.
24. Zhang, S.H., R.L. Reddick, B. Burkey, and N. Maeda. 1994. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94:937-945.
25. Gordon, D.J., and B.M. Rifkind. 1989. High-density lipoprotein: the clinical implications of recent studies. N. Eng. J. Med. 321:1311-1316.
26. Nestel, P.J., and T. Billington. 1981. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis. 38: 203-209.
27. Tawara, K., M. Tomikawa, and Y. Abiko. 1986. Mode of action of probucol in reducing serum cholesterol in mice. Jpn. J. Pharmacol. 40:123-133.
28. Beynen. A.C. 1986. Discrepancies between the outcome of animal and human studies on the mode of action of probucol. Atherosclerosis. 61:249-251.
29. Atmeh, R.F., M.J. Stewart, D.E. Boag, C.J. Packard, A.R. Lorimer, and J. Shepherd. 1983. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. J. Lipid Res. 24:588-595.
30. Hayek, T., T. Chjek-Shaul, A. Wals, N. Azrolan, and J.L. Breslow. 1991. Probucol decreases apolipoprotein AI transport rate and increases high density lipoprotein cholesterol ester fractional catabolic rate in control and human apolipoprotein AI transgenic mice. Arterioscler. Thromb. 11:1295-1302.
31. Steinberg, D. 1986. Studies on the mechanism of action of probucol. Am. J. Cardiol. 57:16H-21H.
32. Bjorkham, I., A. Henrucksson-Freyschuss, O. Breuer, U. Diczfalusy, L. Berglund, and P. Henrikson. 1991. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11:15-22.
33. Tangirala, R.K., F. Casanada, E. Millwe, J.L. Witztum, D. Steinberg, and W. Palinski. 1995. Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. 15:1625-1630.
34. Elinder, L.S., K. Hadell, J. Johansson, J. Molgaard, I. Holme, A.G. Olsson, and G. Walldius. 1995. Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler. Thromb. Vasc. Biol. 15:1057-1063.
35. Snankar, R., J.D. Sallis, H. Stanton, and R. Thomson. 1989. Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats. Atherosclerosis. 78:91-97.
36. Ishibashi, S., J.L. Goldstein, M.S. Brown, J. Herz, and D.K. Barns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1885-1893.
37. Purcell-Huynh, D.A., R.V. Farese, Jr., D.F. Johnson, L.M. Flynn, V. Pierotti, D.L. Newland, M.F. Linton, D.A. Sanan, and S.G. Young. 1995. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesion in response to a high-fat diet. J. Clin. Invest. 95:2246-2257.
38. Callow, M.J., J. Verstuyft, R. Tangirala, W. Palinski, and E.M. Rubin. 1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J. Clin. Invest. 96:1639-1646.